Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 7, 2015, Pages 582-592

  Pichereau, Solen ^a   Zhao, Xia ^b   Cui, Yimin ^b   Zhao, Shuai ^c   Hohl, Kathrin ^a   Meinicke, Thomas ^a   Friedrich, Christian ^d  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd   (China)

^d BAYER PHARMA AG   (Germany)

Author keywords

Bioavailability; Bioequivalence; Linagliptin metformin

Indexed keywords

LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; METFORMIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG COMBINATION; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TABLET;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; ASIAN CONTINENTAL ANCESTRY GROUP; BIOAVAILABILITY; BLOOD; CHINA; COMPARATIVE STUDY; DRUG COMBINATION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; TABLET; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CHINA; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; METFORMIN; PURINES; QUINAZOLINES; TABLETS; YOUNG ADULT;

EID: 84936747423     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202237     Document Type: Article

References (31)

1. International Diabetes Federation. Diabetes Atlas, sixth edition. Available at: http://www.idf.org/sites/default/files/EN-6E-Atlas-Full-0.pdf. Last accessed July 24, 2014.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2015; 38: 140-149. CrossRef PubMed
3. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15: 540-559. CrossRef PubMed
4. Trajenta. Summary of Product Characteristics. Boehringer Ingelheim. Available at: http://www.medicines.org.uk/emc/medicine/25000/SPC/Trajenta+5+mg+film-coated+tablets/. Last accessed July 24, 2014.
5. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011; 13: 258-267. CrossRef PubMed
6. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 653-661. CrossRef PubMed
7. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 65-74. CrossRef PubMed
8. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012; 51: 411-427. CrossRef PubMed
9. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010; 19: 133-140. CrossRef PubMed
10. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs. 2011; 71: 611-624. CrossRef PubMed
11. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011; 27: 1157-1168. CrossRef PubMed
12. Friedrich C, Jungnik A, Retlich S, Ring A, Meinicke T. Bioequivalence of linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial. Drug Res (Stuttg). 2014; 64: 269-275. 10.1055/s-0033-1357144 PubMed
13. Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012; 28: 1465-1474. CrossRef PubMed
14. Buschke S, Ring A, Friedrich C, Metzmann K, Meinicke T. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets. Int J Clin Pharmacol Ther. 2014; 52: 537-548. 10.5414/CP201960 PubMed
15. U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products- general considerations. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf. Last accessed July 24, 2014.
16. European Medicines Agency. Committee for Medicinal Products for Human use (CHMP). Guideline on the investigation of bioequivalence. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf. Last accessed July 24, 2014
17. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008; 48: 1171-1178. CrossRef PubMed
18. Guidance for Industry. Bioanalytical method validation. Rockville, MD: U.S. Food and Drug Administration, Rockville, MD; 2001. Available from: http://www.fda.gov/downloads/Drugs/Guida?nces/ucm070107.pdf.: Last accessed January 14, 2015.
19. Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther. 2010; 32: 1188-1204. CrossRef PubMed
20. Friedrich C, Shi X, Zeng P, Ring A, Woerle HJ, Patel S. Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2012; 50: 889-895. CrossRef PubMed
21. Friedrich C, Glund S, Lionetti D, Kissling CJ, Righetti J, Patel S, Graefe-Mody U, Retlich S, Woerle HJ. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013; 76: 445-454. CrossRef PubMed
22. Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012; 74: 75-85. CrossRef PubMed
23. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009; 11: 786-794. CrossRef PubMed
24. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281: 2005-2012. CrossRef PubMed
25. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 3598-3604. CrossRef PubMed
26. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008; 4: 653-664. PubMed
27. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003; 5: 424-431. CrossRef PubMed
28. Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012; 29: 26-40. CrossRef PubMed
29. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120: 713-719. CrossRef PubMed
30. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 103: 491-497. CrossRef PubMed
31. Metzmann K, Schnell D, Jungnik A, Ring A, Theodor R, Hohl K, Meinicke T, Friedrich C. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. Int J Clin Pharmacol Ther. 2014; 52: 549-563. 10.5414/CP201961 PubMed